Loading
Latest filing published 27 Dec 2024 for Quoin Pharmaceuticals, Ltd., €53k.
Based on 6 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Gordon Dunn appears in our data through filings on Quoin Pharmaceuticals, Ltd. shares, published by SEC (Form 4). The record holds 6 filings, for trades running from 9 September 2024 to 23 December 2024.
The open-market record is one-sided, with 6 purchases worth €74k and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
The median purchase comes to €4,671. On 6 out of 6 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. For 6 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 83% of cases, with a median move of +18.8%. Past outcomes like these are no guarantee of what comes next.
On 27 December 2024 came the latest disclosure, an open-market purchase for €53k in Quoin Pharmaceuticals, Ltd. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations